Though our data represents a relatively small cohort of tumor samples, we have found suggestive evidence that for some targeted drugs, such as PIK3CA inhibitors, there could be value in using dogs with naturally occurring mammary tumors as comparative models. This evidence concerns the gene PIK3CA and breast cancer.